These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21884685)

  • 1. Interference of deferasirox with assays for serum iron and serum unsaturated iron binding capacity during iron chelating therapy.
    Ikuta K; Ito S; Tanaka H; Sasaki K; Torimoto Y; Fujiya M; Kohgo Y
    Clin Chim Acta; 2011 Nov; 412(23-24):2261-6. PubMed ID: 21884685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
    Chen CH; Shu KH; Yang Y
    Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.
    Watanabe J; Sato K; Horiuchi T; Kato S; Hikota R; Maekawa T; Yamamura T; Kobayashi A; Osawa Y; Kobayashi S; Kimura F
    Int J Hematol; 2014 Sep; 100(3):254-9. PubMed ID: 24986748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
    Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
    Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy.
    Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Prossomariti L
    Acta Haematol; 2010; 123(2):117-20. PubMed ID: 20068283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats.
    Brewer C; Otto-Duessel M; Lykkesfeldt J; Nick H; Wood JC
    Exp Hematol; 2012 Oct; 40(10):820-7. PubMed ID: 22713799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.
    Saeki I; Yamamoto N; Yamasaki T; Takami T; Maeda M; Fujisawa K; Iwamoto T; Matsumoto T; Hidaka I; Ishikawa T; Uchida K; Tani K; Sakaida I
    World J Gastroenterol; 2016 Oct; 22(40):8967-8977. PubMed ID: 27833388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
    Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
    Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD; Taher A
    Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative stress and antioxidant capacity in sickle cell anaemia patients receiving different treatments and medications for different periods of time.
    Belini Junior E; da Silva DG; Torres Lde S; de Almeida EA; Cancado RD; Chiattone C; Bonini-Domingos CR
    Ann Hematol; 2012 Apr; 91(4):479-89. PubMed ID: 21947087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events.
    Huang WF; Chou HC; Tsai YW; Hsiao FY
    Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1176-82. PubMed ID: 24946110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
    Ghoti H; Fibach E; Westerman M; Gordana O; Ganz T; Rachmilewitz EA
    Br J Haematol; 2011 Apr; 153(1):118-20. PubMed ID: 21332711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological evaluation of β-thalassemia major patients receiving oral iron chelator deferasirox.
    Aleem A; Shakoor Z; Alsaleh K; Algahtani F; Iqbal Z; Al-Momen A
    J Coll Physicians Surg Pak; 2014 Jul; 24(7):467-71. PubMed ID: 25052967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis.
    Qadah T
    J Int Med Res; 2022 Dec; 50(12):3000605221143290. PubMed ID: 36562113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelation therapy in MDS: what have we learnt recently?
    Schmid M
    Blood Rev; 2009 Dec; 23 Suppl 1():S21-5. PubMed ID: 20116636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of deferasirox in North Indian β-thalassemia major patients: a preliminary report.
    Panigrahi I; Vaidya PC; Bansal D; Marwaha RK
    J Pediatr Hematol Oncol; 2012 Jan; 34(1):51-3. PubMed ID: 22215098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
    Lee SE; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Park CW; Lee JW
    Acta Haematol; 2013; 129(2):72-7. PubMed ID: 23154600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
    Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
    BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferasirox--current knowledge and future challenges.
    Porter JB
    Ann N Y Acad Sci; 2010 Aug; 1202():87-93. PubMed ID: 20712778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.